The Sackler Family and the Opioid Crisis

//The Mainstream Narrative

Purdue Pharma introduced OxyContin in 1996 as a breakthrough pain medication, marketing it as less addictive than other opioids due to its time-release formula. The Sackler family became billionaires while overdose deaths skyrocketed. After lawsuits from states and families, Purdue pleaded guilty to federal criminal charges in 2020, and a controversial bankruptcy settlement granted the Sacklers immunity from civil liability in exchange for $6 billion.

//Under-Reported Dimensions

Internal Purdue documents revealed the family was directly involved in aggressive marketing tactics—not merely passive owners. Richard Sackler personally pushed to "blame" addicted patients and directed sales strategies targeting high-prescribing doctors. The family extracted over $10 billion from Purdue between 2008-2018, even as lawsuits mounted, transferring wealth to offshore accounts and trusts. The bankruptcy immunity deal was extraordinary: non-bankrupt individuals (the Sacklers) receiving legal protection typically reserved for bankrupt entities.

Purdue's influence extended beyond marketing. The company funded pain advocacy groups, medical education, and helped shape clinical guidelines that encouraged opioid prescribing. The "fifth vital sign" campaign—treating pain as aggressively as temperature or blood pressure—was partly funded by opioid manufacturers. FDA reviewers who approved OxyContin later joined companies benefiting from opioid sales.

//Credible Dissenting Voices

Some pain specialists argue the pendulum has swung too far, with chronic pain patients now unable to access necessary medications due to overly restrictive policies. They contend the crisis stems more from illicit fentanyl than prescription opioids, and that focusing solely on the Sacklers obscures systemic failures across medicine, insurance, and regulatory agencies.

//Follow the Money

The Sacklers donated over $1 billion to museums, universities, and medical institutions—donations that secured naming rights and institutional prestige. Many institutions only removed the Sackler name after 2019. The family divided into multiple branches, with some claiming no involvement in Purdue's operations, though all benefited financially.

//Open Questions

Will the Supreme Court uphold the bankruptcy settlement granting Sackler immunity? How did the FDA approve OxyContin's original labeling claiming reduced abuse potential without adequate evidence? What role did pharmacy benefit managers and insurers play in the crisis? How much Sackler wealth remains hidden in complex trusts and foreign accounts?